Reduction of Opioid Dependency Phase I/Phase II Clinical Trials

In response to the critical need for non-opioid interventions in addressing opioid addiction, ANANDA Scientific is conducting groundbreaking research on the potential of cannabidiol (CBD) as a viable treatment strategy. Preliminary findings from preclinical rat studies indicate that CBD has the capacity to reduce heroin-seeking behavior.

Led by Yasmin Hurd, PhD at Mt. Sinai, in first of a series of planned trials, a Phase I trial evaluating the pharmacokinetic profile, safety, and drug tolerability of Nantheia™ ATL5 Ananda’s investigational CBD drug utilizing it proprietary Liquid Structure ™ delivery technology, in comparison to Epidolex™ has been completed. This trial involves 24 subjects and focused on assessing plasma PK parameters, urinary excretion of CBD and metabolites, and various safety assessments in healthy subjects. For more detailed information, refer to the clinical trials.gov link here.

To delve deeper into this endeavor, explore the associated press release here. This collaboration between ANANDA Scientific and Mt. Sinai Hospital stands as a promising step towards addressing opioid dependency, exemplifying our commitment to innovative and responsible healthcare solutions.

For more details, refer to the clinicaltrials.gov link (https://clinicaltrials.gov/study/NCT05023070) and press releases issued over the course of the study:

ANANDA Scientific’s Liquid Structure™ Cannabidiol (CBD) to Be Clinically Evaluated for Opioid Use Disorder – Mt Sinai Hospital